Accretion Nutraveda IPO: A High-Growth Bet on Ayurvedic CDMO and Global Wellness
Accretion Nutraveda Limited, a Gujarat-based healthcare manufacturer specializing in over 400 Ayurvedic and nutraceutical formulations, is launching its ₹24.77 crore SME IPO. This post breaks down the company’s massive revenue growth, its global footprint across 20+ countries, and the essential bidding details for investors looking to participate between January 27 and January 30, 2026.
Live IPO Tracking Available
Check live GMP, allotment status, and deep analysis for this IPO.
1. Who is Accretion Nutraveda Limited?
Incorporated in 2021, Accretion Nutraveda operates as a specialized Contract Development and Manufacturing Organization (CDMO). They bridge the gap between traditional Ayurvedic wisdom and modern nutraceutical science, producing everything from liver care supplements to cognitive health boosters.
Their Diversified Product Portfolio Includes:
Tablets & Capsules: Targeted at bone health, women's wellness, and respiratory support.
Oral Liquids & Powders: Including traditional syrups, tonics, and "Churans" for digestive health.
Topical Preparations: Medicated oils, balms, and creams for pain relief and dermatological care.
Global Reach: While 96% of revenue is domestic/merchant exports, they have a growing direct presence in the USA, Singapore, and Sri Lanka.
2. Key IPO Details & Timeline
The IPO is a Book Built Issue consisting entirely of a Fresh Issue of 19.20 lakh shares.
| Event | Date / Details |
|---|---|
| IPO Open Date | Tuesday, January 27, 2026 |
| IPO Close Date | Friday, January 30, 2026 |
| Price Band | ₹122 to ₹129 per share |
| Lot Size | 1,000 Shares |
| Minimum Investment (Retail) | ₹2,58,000 (Min 2 Lots / 2,000 shares) |
| Allotment Finalization | Monday, February 2, 2026 |
| Listing Date (Tentative) | Wednesday, February 4, 2026 |
| Listing Platform | BSE SME |
3. Financial Highlights: A Triple-Digit Growth Story
Accretion Nutraveda has demonstrated an explosive growth curve since its inception:
Revenue Growth: Revenue from operations jumped from ₹2.90 Cr in FY23 to ₹16.06 Cr in FY25.
Profitability: Profit After Tax (PAT) surged from ₹0.28 Cr to ₹2.61 Cr in the same period.
Stellar Margins: Boasts an EBITDA margin of 22.79% and a PAT margin of 16.33% (FY25).
Efficiency: Reported a Return on Net Worth (RoNW) of 48.85%, showcasing high efficiency in capital utilization.
4. Objectives of the Issue
The company is focused on scaling up production to meet rising global demand:
New Manufacturing Setup (₹8.03 Cr): Investing in machinery for a brand-new facility.
Automation (₹4.22 Cr): Upgrading current units with automated machinery to increase speed and precision.
Working Capital (₹5.50 Cr): Supporting the daily operational cycle and raw material procurement.
General Corporate Purposes: General overheads and brand expansion.
5. Investment Analysis: Strengths vs. Risks
Strengths:
Niche Moat: Specialized CDMO focus allows them to serve multiple brands without the heavy cost of direct marketing.
High Quality Standards: Their facility in Sanand, Gujarat is WHO-GMP and ISO certified, which is critical for international exports.
Experienced Promoters: Led by pharma veterans with over a decade of experience in international business and R&D.
Risks:
Client Concentration: A significant portion of revenue is dependent on a small group of large corporate clients.
Leased Assets: Both their current registered office and factory are on leased premises.
Regulatory Sensitivity: Any change in Ayurvedic or FSSAI regulations can impact the entire product pipeline.
6. Conclusion
Accretion Nutraveda is entering the market with a P/E ratio of approximately 35x (based on FY25 earnings). While this is a premium valuation, it is backed by a 212% CAGR in revenue. For investors looking for exposure to the "Wellness Revolution" and the booming SME pharma sector, this issue offers a high-margin, asset-light manufacturing play.